Results of a Phase Ib Trial of Combination Immunotherapy With a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

According to researchers, the GP2 + GM-CSF vaccine is safe and stimulates an immunologic response when administered concurrently with trastuzumab patients with breast cancer. An ongoing phase II trial is evaluating the efficacy of combining a CD8 T-cell-eliciting vaccine with trastuzumab in HER2-positive breast cancer patients.

 Ann Surg Oncol

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.